Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
McKinsey
Moodys
Harvard Business School
Dow

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR DEPAKOTE ER


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Depakote Er

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00005015 ↗ Treatment of Depression in Youth With Bipolar Disorders Terminated National Institute of Mental Health (NIMH) Phase 3 1969-12-31 THIS STUDY HAS BEEN DISCONTINUED. The study is designed to evaluate the safety and efficacy of fluoxetine for treating children and adolescents with Bipolar Disorder who are experiencing an episode of major depression while being treated with a mood stabilizer. The study involves a 2-week assessment period. Patients who are on stable, therapeutic doses of lithium or valproate and continue to have depression will be randomized to a 12-week treatment of fluoxetine or placebo. Those who respond favorably to treatment will be followed openly for an 18-week continuation phase.
NCT00048802 ↗ Treatment and Outcome of Early Onset Bipolar Disorder Completed National Institute of Mental Health (NIMH) Phase 4 2002-08-01 This study will compare the effectiveness in the maintenance of continuing adjunctive atypical antipsychotic medication compared to traditional mood stabilizer(s) alone in the maintenance treatment of adolescents with bipolar disorder.
NCT00048802 ↗ Treatment and Outcome of Early Onset Bipolar Disorder Completed Northwell Health Phase 4 2002-08-01 This study will compare the effectiveness in the maintenance of continuing adjunctive atypical antipsychotic medication compared to traditional mood stabilizer(s) alone in the maintenance treatment of adolescents with bipolar disorder.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Depakote Er

Condition Name

Condition Name for Depakote Er
Intervention Trials
Bipolar Disorder 26
Healthy 16
Schizophrenia 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Depakote Er
Intervention Trials
Bipolar Disorder 32
Disease 24
Depression 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Depakote Er

Trials by Country

Trials by Country for Depakote Er
Location Trials
United States 205
India 8
Canada 3
Korea, Republic of 2
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Depakote Er
Location Trials
Texas 17
Ohio 15
Illinois 13
California 13
New York 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Depakote Er

Clinical Trial Phase

Clinical Trial Phase for Depakote Er
Clinical Trial Phase Trials
Phase 4 29
Phase 3 18
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Depakote Er
Clinical Trial Phase Trials
Completed 73
Terminated 10
Unknown status 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Depakote Er

Sponsor Name

Sponsor Name for Depakote Er
Sponsor Trials
Abbott 33
National Institute of Mental Health (NIMH) 10
Dr. Reddy's Laboratories Limited 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Depakote Er
Sponsor Trials
Other 79
Industry 63
NIH 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Express Scripts
Baxter
AstraZeneca
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.